Journal
ACS CHEMICAL BIOLOGY
Volume 8, Issue 11, Pages 2360-2365Publisher
AMER CHEMICAL SOC
DOI: 10.1021/cb4003283
Keywords
-
Categories
Funding
- Reproductive Branch of the National Institutes of Child Health and Human Development [3U01HD076542-01S1]
Ask authors/readers for more resources
Bromodomain-containing proteins are considered atypical kinases, but their potential to interact with kinase inhibitors is unknown. Dinaciclib is a potent inhibitor of cyclin-dependent kinases (CDKs), which recently advanced to Phase III clinical trials for the treatment of leukemia. We determined the crystal structure of dinaciclib in complex with CDK2 at 1.7 angstrom resolution, revealing an elaborate network of binding interactions in the ATP site, which explains the extraordinary potency and selectivity of this inhibitor. Remarkably, dinaciclib also interacted with the acetyl-lysine recognition site of the bromodomain testis-specific protein BRDT, a member of the BET family of bromodomains. The binding mode of dinaciclib to BRDT at 2.0 angstrom resolution suggests that general kinase inhibitors (hinge binders) possess a previously unrecognized potential to act as protein-protein inhibitors of bromodomains. The findings may provide a new structural framework for the design of next-generation bromodomain inhibitors using the vast chemical space of kinase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available